Navigation Links
Patent Issued on Fusion-Protein Vaccine Technology
Date:2/29/2012

NEWARK, Del., Feb. 29, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced issuance of a US patent covering the use of iBio's proprietary fusion-protein technology in combination with influenza virus antigens for vaccine product applications. The invention comprises the use of lichenase in an adjuvant-like role to improve the performance of vaccines. This approach was developed by the Fraunhofer USA Center for Molecular Biotechnology (FhCMB), iBio's research collaborator. The new patent is US Patent 8,124,103, entitled "Influenza Antigen, Vaccine Compositions, and Related Methods".

The vaccine industry is increasingly focused on the development of subunit vaccines. These subunit vaccines require use of components called adjuvants for improving their efficacy. Lichenase, when fused to antigens acts as an adjuvant and can improve the efficacy of vaccines.  Fusion of lichenase to vaccine antigens can enhance duration of immune response, improve production economies and increase product stability.  This approach could provide significant advantages over more conventional methodologies used to improve vaccine efficacy.

"We consider the issuance of this patent to be an important step in the expansion of opportunities in subunit vaccine development," said Vidadi Yusibov, Ph.D., one of the patent's inventors and Executive Director of FhCMB. "We previously published data demonstrating significant improvement in candidate vaccine performance in animal models when lichenase technology is employed with a range of target antigens, including antigens from plague, malaria, and human papilloma virus."

"While iBio's principal focus has been to optimize and commercialize our proprietary platform technology for broad commercial applications across the biologics field, we also have been bringing forward lichenase as a separate proprietary product platform to be licensed to enhance vaccine performance," said Robert B. Kay, Executive Chairman and CEO of iBio.  "Based upon the results obtained in multiple animal studies and the formulation advantages of using a fusion protein, we believe there will be substantial commercial interest in lichenase as a proprietary approach for potent subunit vaccines."

This patent is an important addition to iBio's broader intellectual property portfolio that includes the clinical-stage iBioLaunch™ platform for vaccines and therapeutic products. 

About iBio, Inc.iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of vaccines and therapeutic proteins using transient gene expression in green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.

About Fraunhofer USA Center for Molecular BiotechnologyFraunhofer USA CMB, a division of Fraunhofer USA, Inc., is a not-for-profit research organization whose mission is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. The Center conducts research in the area of plant biotechnology, utilizing new, cutting edge technologies to assist with the diagnosis, prevention and treatment of human and animal diseases. The Center houses individuals with expertise and excellence in plant virology, pathology, molecular biology, immunology, vaccinology, protein engineering, and biochemistry. Further information is available at www.fraunhofer-cmb.org.

Forward-Looking StatementsStatements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

 Contacts:  

 Corporate:Investor: 

 Robert Erwin, PresidentDouglas Beck, CFOiBio, Inc.iBio, Inc.302-355-2335302-355-9452rerwin@ibioinc.comir@ibioinc.com  


'/>"/>

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma® Life Science Obtains Global License for Kyoto Universitys iPS Cell Patent Portfolio, Deepens Commitment to Drug Discovery and ADME/Toxicology
2. Xenogenics Received Rights to Polyanhydride Compounds Drug Delivery Patent
3. Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc.
4. New Patent Promises to Accelerate Cancer Trials
5. Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings
6. Prismic Pharmaceuticals Acquires Scaristas Exclusive License to Amarins Omega-3 Patents for CNS Disorders
7. IntraOp Medical wins Patent Defense Suit Protecting Their Intellectual Property
8. Nautilus Neurosciences Announces New Patent Issued
9. Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex
10. Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Companys Core Technology in Oral Delivery of Proteins
11. Perrigo Confirms Filing for Generic Version of Astepro® Nasal Spray and Announcement of Patent Infringement Lawsuit by Meda Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):